SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics, a company specializing in skin health, has announced the conversion of £160,000 in Convertible Bonds, reducing their outstanding bonds to £480,000. They will issue nearly 2 million new ordinary shares at a price of 8.040687p each, with the admission of these shares to the AIM expected on 24 July 2024, bringing the total issued shares to 205,361,916. This marks a significant move for shareholders and the market as the company continues to develop its skin health-focused technology platform, SkinBiotix, and its first product, AxisBiotix-Ps™, for psoriasis symptoms.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
